Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry D Lebowitz

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Clinical Psychopharmacology|March 18, 2008
Assessment of medication management ability in middle-aged and older adults with bipolar disorderColin A Depp, Ashley E Cain, Barton W Palmer, et al.
Journal of Psychiatric Research|August 5, 2014
Cognitive functioning in complicated griefCharles A Hall, Charles F Reynolds, Meryl Butters, et al.
The International Journal of Neuropsychopharmacology|May 10, 2005
The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetineGeorge I Papakostas, Timothy Petersen, Barry D Lebowitz, et al.
Journal of Psychiatric Research|October 9, 2017
Medical comorbidity in complicated grief: Results from the HEAL collaborative trialGregg Robbins-Welty, Sarah Stahl, Jun Zhang, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
The American Journal of Psychiatry|April 17, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD studyLing Zheng, Wendy J Mack, Karen S Dagerman, et al.
The New England Journal of Medicine|March 24, 2006
Medication augmentation after the failure of SSRIs for depressionMadhukar H Trivedi, Maurizio Fava, Stephen R Wisniewski, et al.
Archives of General Psychiatry|November 7, 2007
Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer diseaseRobert A Rosenheck, Douglas L Leslie, Jody L Sindelar, et al.
Current Psychiatry Reports|October 22, 2010
Biomarkers to predict antidepressant responseAndrew F Leuchter, Ian A Cook, Steven P Hamilton, et al.
The New England Journal of Medicine|September 21, 2005
Effectiveness of antipsychotic drugs in patients with chronic schizophreniaJeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Clinical Psychopharmacology|March 18, 2008
Assessment of medication management ability in middle-aged and older adults with bipolar disorderColin A Depp, Ashley E Cain, Barton W Palmer, et al.
Journal of Psychiatric Research|August 5, 2014
Cognitive functioning in complicated griefCharles A Hall, Charles F Reynolds, Meryl Butters, et al.
The International Journal of Neuropsychopharmacology|May 10, 2005
The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetineGeorge I Papakostas, Timothy Petersen, Barry D Lebowitz, et al.
Journal of Psychiatric Research|October 9, 2017
Medical comorbidity in complicated grief: Results from the HEAL collaborative trialGregg Robbins-Welty, Sarah Stahl, Jun Zhang, et al.
The American Journal of Psychiatry|June 4, 2008
Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trialDavid L Sultzer, Sonia M Davis, Pierre N Tariot, et al.
The American Journal of Psychiatry|April 17, 2009
Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD studyLing Zheng, Wendy J Mack, Karen S Dagerman, et al.
The New England Journal of Medicine|March 24, 2006
Medication augmentation after the failure of SSRIs for depressionMadhukar H Trivedi, Maurizio Fava, Stephen R Wisniewski, et al.
Archives of General Psychiatry|November 7, 2007
Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer diseaseRobert A Rosenheck, Douglas L Leslie, Jody L Sindelar, et al.
Current Psychiatry Reports|October 22, 2010
Biomarkers to predict antidepressant responseAndrew F Leuchter, Ian A Cook, Steven P Hamilton, et al.
The New England Journal of Medicine|September 21, 2005
Effectiveness of antipsychotic drugs in patients with chronic schizophreniaJeffrey A Lieberman, T Scott Stroup, Joseph P McEvoy, et al.
Pageof 5